Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
| Autor: | M. D. Caballero, Carlos Vallejo, S G Perez, Eulogio Conde, Guillermo Sanz, Jaime Sanz, D Serrano, Arancha Bermúdez, José M. Moraleda, J.J. Lahuerta, J. de la Serna, M. Cabrero, Valle Gomez |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Mucositis medicine.medical_specialty Transplantation Conditioning Hepatic Veno-Occlusive Disease Graft vs Host Disease Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Recurrence Internal medicine medicine Humans Cumulative incidence Busulfan Survival analysis Aged Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Myeloablative Agonists medicine.disease Survival Analysis Fludarabine Surgery Regimen Leukemia Myeloid Acute Graft-versus-host disease 030220 oncology & carcinogenesis Histocompatibility Myelodysplastic Syndromes business Vidarabine 030215 immunology medicine.drug |
| Zdroj: | Bone marrow transplantation. 51(7) |
| ISSN: | 1476-5365 |
| Popis: | The safety and efficacy of a 4-day myeloablative conditioning (MAC) regimen consisting of Bu 3.2 mg/kg and fludarabine 40 mg/m2/day for HLA-identical sibling allogeneic hematopoietic cell transplantation (HCT) in myeloid malignancies was investigated in 133 patients (median age, 47 years; range 19–74 years) with de novo AML (60%), secondary AML (20%) or myelodysplastic syndrome (20%). All patients engrafted. Hepatic veno-occlusive disease occurred in five patients (4%), and severe toxicities, mostly mucositis, occurred in twenty-three (17%) patients. The non-relapse mortality (NRM) at 100 days was 1.5%. The incidences of acute GVHD grade 2–4 and grade 3–4 were 32 and 13%, respectively. At a median follow-up of 38 months, the cumulative incidence of chronic GVHD was 67%. The relapse incidence was 30% (27 and 31%, respectively, in patients with early- and late-stage disease), and the overall NRM was 15%. The actuarial 4-year disease-free survival (DFS) and overall survival (OS) were 54 and 62%, respectively. Patients aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink